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11.1  Introduction
Synthetic biology constitutes a new field of research, in which scientists are gaining 
more and more control over the fundamental building blocks of life. This allows 
them to ‘design’ and ‘create’ microorganisms that may perform a variety of useful 
tasks, but at the same time become increasingly isolated from organisms we may 
find in nature. Given the potential of synthetic biology to contribute to addressing 
important challenges in, for example, health, the scarcity of resources and energy 
security, it is no surprise that this field has been embraced as a promising scientific 
endeavour by scientists all over the globe. On the other hand, like agro-biotechnol-
ogy and nanotechnologies—or any other field of science and technology, for that 
matter—synthetic biology also gives rise to concerns about potential risks. In addi-
tion, it raises moral questions and concerns, since it allows scientists to put ‘life’ 
and ‘nature’ on the drawing board as never before.
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Synthetic biology may thus—once more, like any other science or technology— 
also lead to tensions (and even conflict) and therefore debate. The nature and 
dynamics of these tensions and debates are, however, not solely informed by the 
character of a particular science or technology; they are also informed by the spe-
cific socioeconomic conditions, cultures and values in a given locality, which will 
therefore be taken into account in our comparative analysis of the three regions. 
Furthermore, we see synthetic biology as a global endeavour, contributing to an 
increased global interconnectedness. This is expressed, for instance, by increas-
ing international scientific cooperation, but also by potential risks that are not con-
strained by state borders.
The contribution of synthetic biology to this increased global interconnected-
ness was recently underscored by the Global Network of Science Academies (IAP) 
(IAP 2014a).1 The IAP issued a statement appealing for global commitment 
regarding synthetic biology, recommending continuing worldwide collaboration 
between researchers and those regulating and enabling synthetic biology, and also 
calling for controversial issues to be settled. However, as we previously men-
tioned, moral concerns may lead to tension within a specific region, but also 
between different regions.
Against the backdrop of these region-specific traits and global interconnect-
edness, this chapter will analyse and compare the emerging debate on synthetic 
biology in the EU, China and India. The analysis will be based primarily on three 
reports of the Global Ethics in Science and Technology (GEST) project, each 
focusing on discourses on synthetic biology in the region concerned (Stemerding 
and Rerimassie 2013; Zhang 2014; Srinivas 2014). We consider the debate in the 
EU rather mature in comparison with those in the other regions, and moreover 
believe that it reflects many traits of the international debate on synthetic biology. 
We will therefore use the European debate as a starting point, and then highlight 
region-specific traits in China and India.
In conducting this analysis we will use the analytical framework described in 
Chap. 8, thus analysing discourses on innovation, risk, and power and control. 
In addition, we will focus on two crosscutting discourses: first, public debates 
expressing lay morality—what expectations and issues have been raised concern-
ing synthetic biology by voices from civil society and the broader public?—and 
second, how reflective ethics voices have engaged with synthetic biology in the 
three regions. We will examine the nature of each discourse: that is, what kinds 
of issues are discussed and to what values do they relate? What kinds of actors 
take part in the discussion? Then we will consider whether certain discourses are 
dominant. This will allow a comparative analysis of the three regions, which will 
consider similarities and differences.
1
 The Global Network of Science Academies consists of 106 scientific academies from all over 
the world, including the EU, China and India (IAP 2014b).
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Throughout this endeavour we will pay specific attention to the role of region-
specific values, as described in Chaps. 5, 6 and 7, in the debate. We will begin, 
however, by briefly describing the understanding, framing and state of the art of 
synthetic biology in the three regions, since its understanding and the degree of 
development are highly likely to be core parameters for the nature, and even emer-
gence, of the different discourses in the three regions.
11.2  Understanding Synthetic Biology
The theoretical basis of the contemporary understanding of synthetic biology is 
attributed largely to Waclaw Szybalski, who proclaimed in 1974:
Up to now we are working on the descriptive phase of molecular biology. … But the real 
challenge will start when we enter the synthetic biology phase of research in our field. We 
will then devise new control elements and add these new modules to the existing genomes 
or build up wholly new genomes. This would be a field with unlimited expansion potential 
and hardly any limitations to building ‘new better control circuits’ and … finally other 
‘synthetic’ organisms … (EGE 2009).2
Thus, according to Szybalski, biology will eventually evolve into a different kind 
of science, in which we shift from describing to designing, or redesigning, life. 
Szybalski’s words have turned out to be prophetic, but it was not until the turn of 
the century that scientists started research under the explicit heading of synthetic 
biology. Interestingly, many of these researchers were not primarily involved in 
molecular biology. Today ‘synthetic biologists’ employ a variety of novel 
approaches, all of which allow increasing control over the fundamental building 
blocks of life. This unique quality can therefore also be found in the definitions 
used in the three regions to describe synthetic biology.3 A definition by a high-
level expert group for the European Commission (NEST 2005), for instance, reads 
as follows:
Synthetic biology is the engineering of biology: the synthesis of complex, biologi-
cally based (or inspired) systems, which display functions that do not exist in nature. 
This engineering perspective may be applied at all levels of the hierarchy of biologi-
cal structures—from individual molecules to whole cells, tissues and organisms. In 
essence, synthetic biology will enable the design of ‘biological systems’ in a rational 
and systematic way.
2
 Luis Campos demonstrates that the label ‘synthetic biology’ can actually already be traced 
back to the beginning of the 20th century. The earliest explicit reference to ‘synthetic biology’ 
comes from the book La biologie synthetique by Stéphane Leduc (1853–1939) (Campos 2009).
3
 For a more detailed account of dominant approaches in synthetic biology see Stemerding and 
Rerimassie (2013).
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The Indian Task Force on Synthetic and Systems Biology Resource Network 
pr oduced the following, quite similar, definition:
Synthetic biology refers to both:
•	 	the design and fabrication of biological components and systems that do not already 
exist in the natural world; and
•	 the re-design and fabrication of existing biological systems (SSBRN 2012).
In the official China Biotechnological Development Report, synthetic biology is 
described as:
… a new trend of biotechnological development … to form new biological systems and 
achieve expected industrial application (Department of Science and Technology for Social 
Development under the Ministry of Science and Technology of China, China National 
Center for Biotechnology Development 2009).
Synthetic biology is thus commonly understood as the application to biology of 
a true engineering approach, in order to design, or redesign, organisms that are 
useful for society.
11.2.1  Framing of Synthetic Biology as an Emerging 
and Converging Technology
The emergence and introduction of new science and technology in society are, 
more often than not, accompanied by tensions and conflicts. However, as a new 
and emerging field of engineering, synthetic biology is still largely at a laboratory 
stage. Therefore discussions about synthetic biology as a potential source of ten-
sions and conflicts will be strongly influenced by experiences with other science 
and technology developments in the recent past:
To debate a still quite abstract technology, participants functionally need a frame that 
determines which arguments are legitimate and which issues are relevant (Torgersen and 
Schmidt 2013).
According to Torgersen and Schmidt, three fields of science and technology cur-
rently provide important frames for discussing synthetic biology: (green) biotech-
nology, nanotechnology and information technology.4 This makes even more 
sense, because synthetic biology is often considered to be enabled by so-called 
‘NBIC convergence’: the synergetic convergence of nanotechnologies, biotechnol-
ogies, information and communications technologies and, though less relevant in 
this context, cognitive sciences (Van Est and Stemerding 2012).
4
 ‘In the biotechnology debate, risk has long been emphasised over economic benefits. More 
recently, nanotechnology has been referred to mostly in terms of benefits, while risks tended to 
be an issue for scientific discourses. This has frequently been related to the many outreach activi-
ties around nanotechnology. Information technology, finally, has retained the image of being 
“cool” and useful on a personal level’ (Torgersen and Schmidt 2013).
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When looking at the three regions, we must conclude that synthetic  biology 
is predominantly framed, and debated, as a new phase in the development of 
 biotechnology, as illustrated in statements by important spokespersons in the field. 
According to the New and Emerging Science and Technology High-Level Expert 
Group for the European Commission (NEST 2005), synthetic biology could rev-
olutionize the biotechnology industries and perhaps even biology as a science. 
In important symposiums, such as those organized by the China Association for 
Science and Technology, synthetic biology is described by Chinese biologists as 
one of the great frontiers of modern biotechnology. The Indian task force sees syn-
thetic biology as a science of the future, which may change the profile of the bio-
technology industry. Synthetic biology is thus commonly understood in the three 
regions as the next wave in biotechnology, which will also strongly frame soci-
etal debates about its potential implications. Conceived as a new form of ‘extreme 
genetic engineering’, synthetic biology may well add fuel to the ongoing debates 
and controversies surrounding genetically modified organisms (ETC Group 2007).
11.3  The Development of Synthetic Biology in the Three 
Regions: The State of the Art
Ever since the turn of the century, synthetic biology has been gaining interna-
tional momentum and the number of published papers has been steadily increas-
ing (Zhang 2014). As illustrated in an interactive map (reproduced in Fig. 11.1) 
produced by the Synthetic Biology Project, which is led by the US-based Woodrow 
Wilson International Center for Scholars, synthetic biology research  activity 
has emerged all over the globe. In addition, there is increasing international 
Fig. 11.1  Map tracking the number of synthetic biology research groups across the globe 
(Reproduced from http://www.synbioproject.org/library/inventories/map/)
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collaboration among synthetic biologists, contributing to an ever growing global 
interconnectedness.
There are significant differences across the three regions in the development of 
synthetic biology, which ranges from rather advanced to just starting. In Europe 
such development is not quite as advanced as in the United States, but is still very 
much at the forefront. Once synthetic biology emerged in the United States, it was 
almost immediately embraced by the European scientific community, and the EU 
(as well as several individual EU member states) rapidly started investing in syn-
thetic biology as well (Stemerding and Rerimassie 2013). By 2014, synthetic biol-
ogy was gradually being applied in industrial settings (Schmidt 2012).
Synthetic biology has also attracted the attention of Chinese researchers, 
although this did not begin happening as early as in Europe. The Chinese gov-
ernment started funding synthetic biology research in about 2008, and ever since 
has given the field more and more support. The development of synthetic biology 
in China is therefore not as advanced as in Europe, but now the country is fully 
equipped to catch up with countries at the forefront (Zhang 2014).
In sharp contrast, synthetic biology has so far gained little attention in India, 
and is as yet largely confined to certain institutes and groups—very few in com-
parison with the number of Indian groups working in life sciences and biotechnol-
ogy. Also the interest from the Indian government and industry is limited so far 
(Srinivas 2014). Accordingly, this chapter’s discussion of the discourses on syn-
thetic biology in India will be primarily based on the findings of the aforemen-
tioned task force, made up of government representatives and academics, which 
was established by the government to examine the opportunities for synthetic biol-
ogy and systems biology for India.
11.4  Comparing Discourses on Synthetic Biology  
in the Three Regions
Preceding chapters have described dominant approaches in synthetic biology 
and observed that in all three regions the field is understood as a new phase in 
the development of biotechnology. It has also been noted, however, that the state 
of the art of the development of synthetic biology differs widely among the three 
regions: development in the EU can be seen as ‘advanced’, in China as ‘rapidly 
catching up’ and in India as ‘just starting’. Against this backdrop, we will now 
analyse and compare how synthetic biology has been debated so far in the three 
regions, based on discourses relating respectively to innovation, to risk, and 
to power and control, and also those concerning lay morality and reflective eth-
ics. We will highlight the issues being discussed, the values to which they relate 
and the actors that play a part in the discourse. A more detailed account of the 
discourses in each region can be found in the three GEST reports on this topic 
(Stemerding and Rerimassie 2013; Zhang 2014; Srinivas 2014).
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11.4.1  Discourses on Innovation
Why is synthetic biology important? What are the opportunities? What can the 
field deliver? What is needed for synthetic biology to mature into an industrially 
relevant and socially robust discipline? These are the central questions of an inno-
vation discourse.
In all three regions voices are heard on the opportunities synthetic biology 
might bring for society. It is perceived as a potentially powerful field of research 
whose applications might help address challenges that all three regions face. Such 
challenges may relate to (public) health, sustainability, energy sources and ecol-
ogy. Synthetic biology is also seen as a vital source of future economic develop-
ment in the context of global competition between the three regions. Thus support 
for synthetic biology should enable China to ‘catch up’ with the US and Europe 
and is called for in India so that the country does not ‘miss the bus’ (Zhang 2014; 
Srinivas 2014).
In Europe, the New and Emerging Science and Technology (NEST) Pathfinder 
funding scheme, set up in 2004, was an important starting point for the develop-
ment of synthetic biology (Pei et al. 2011). It was followed by several other initia-
tives, including those under the Seventh Framework Programme and the road map 
of the project called Towards a European Strategy for Synthetic Biology (TESSY), 
which is dedicated to strategy development for synthetic biology in Europe 
(TESSY 2008; Gaisser et al. 2009). More recently, from 2012 to 2014, came the 
establishment of ERASynBio, a European initiative aimed at the development and 
coordination of synthetic biology in the European research area. One of the impor-
tant aims of this initiative was to comprehensively map national and transnational 
funding programmes, funded synthetic biology projects, relevant strategies and 
reports, and active companies, in order to develop a strategic vision. According to 
these mapping activities, about €450 million of public research funding was allo-
cated to synthetic biology from 2004 to 2014 (ERASynBio 2014) (Fig. 11.2).
Important issues that need to be addressed, according to the ERASynBio net-
work, include building a transnational multidisciplinary research community, 
data sharing, standardization and accelerating the applied and industrial use of 
synthetic biology. Another particularly important issue is what a proper intellec-
tual property regime for synthetic biology would look like. Should it allow broad 
patenting or would an open-source regime be more desirable? As for values, we 
find that the European discourse is predominately informed by values of freedoms, 
including market freedoms, and sustainability (e.g. EASAC 2010). Furthermore, 
in the EU a need is felt to go beyond technoscientific support actions in order to 
make synthetic biology successful, for instance by addressing ethical and regula-
tory concerns early on (e.g. TESSY 2008; OECD, Royal Society 2010). This is 
aptly expressed in a broadly shared call for responsible research and innovation 
(RRI) in synthetic biology (e.g. ERASynBio 2014). Interestingly, in considering 
the innovation potential of synthetic biology, the Indian task force also explicitly 
mentioned issues of risk and ethics as equally important to address.
152 V. Rerimassie et al.
As in Europe, there is in China a strongly developed innovation discourse, from 
which several support actions are apparent, such as capacity and community building 
(Zhang 2014). In many scientific symposia, such as the Xiangshan Science 
Conference sessions, it is evident that Chinese biologists consider synthetic biology 
to be one of the great frontiers of modern biotechnology. These biologists have there-
fore called for government support on many occasions, and not without success. For 
example, synthetic biology is marked as one of the 12 core key technologies for pri-
oritized development in the 12th Five-year Plan for Biotechnological Development 
(MOST 2011) released by the Ministry of Science and Technology. Furthermore, 
synthetic biology has been financed by a series of programmes, such as the 
863 programme,5 the 973 programme6 and the National Natural Science Foundation.
Regarding values, the innovation discourse is informed by the full spectrum of 
Chinese values. Stimulating synthetic biology is expected to contribute to promot-
ing economic development (progress), protecting public health (harmony), safe-
guarding national security and coping with an ageing and growing population 
(peace), and last, addressing resource and environmental needs (sustainability) 
(CNCBD 2010). This illustrates that while ethics is not institutionalized in China 
5
 The 863 programme, or the National High-tech R&D Programme, was approved in 1986 to 
promote high-technology research and development in China. Biotechnology is listed as one of 
its eight priority fields.
6
 The 973 programme, or the National Basic Research Programme of China, was approved in 
1997 to support basic science and technology research. It promotes research and innovation in 
fields of far-reaching and strategic importance, such the life sciences.
Fig. 11.2  Sites of major 
European public investment 
in synthetic biology 
(ERASynBio 2014)
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in the same way as it is in the EU or the US, it certainly has a place in directing 
the course of synthetic biology in China.
India, unlike Europe and China, does not have a strongly developed innovation 
discourse yet. In the recommendations of the Indian task force, however, there is a 
strong link between the identified potential aims for synthetic biology in India and 
the needs of the country, ranging from energy security to improvements in agricul-
ture and health, topics that strongly relate to values of access and equity.
Last, in all three regions the International Genetically Engineered Machine 
competition (iGEM), a synthetic biology design contest for students, is considered 
an important educational, capacity-building and community-building tool (see e.g. 
ERASynBio 2014; SSBRN Task Force 2012; Zhang 2014).
11.4.2  Discourses on Risk
Like any other technology, synthetic biology not only promises potential benefits, 
but also raises concerns about possible risks. What types of risks are perceived? 
By whom? What weight do they assign to the risks in relation to the benefits? How 
should society deal with these potential risks?
The potential risks of synthetic biology make up an important part of the evolv-
ing story of synthetic biology. This is the case for the EU, but also for China and 
India. Two types of categories of risks are distinguished: first, biosafety, relating 
to potential unintended consequences for humankind and the environment, and 
second, biosecurity, relating to potential misuse (e.g. EGE 2009; CNCBD 2010; 
SSBRN Task Force 2012). The fact that all three regions devote attention to these 
issues is no real surprise, however, since EU member states, India and China are 
all party to several international conventions, such as the Cartagena Protocol on 
Biosafety and the Biological Weapons Convention, which call for these issues to 
be addressed as well.
Civil society organizations in Europe, unlike the other regions, are strongly 
involved in the evolving risk discourse. A central value in the European discourse 
is protection as a citizen’s right. In terms of this right, civil society organizations 
demand a strict precautionary approach and also bring in a more inclusive per-
spective of justice, solidarity and equality. Whereas synthetic biology is supported 
in the innovation discourse for its potential contribution to a greener economy, 
civil society organizations challenge it for its detrimental effects on sustainability; 
that is, for promoting the exploitation of natural resources and the communities 
that are dependent on them (FOE et al. 2012). Indeed, similar concerns have been 
voiced in India (Srinivas 2014).
In China risks are also seen as a point of concern, but hampering innovation 
and missing out on the opportunities of synthetic biology are actually perceived 
as much bigger risks by both the government and the scientific community. This 
became clear, for instance, at an academic symposium dedicated to synthetic 
 biology and ethical and biosecurity concerns, organized by the China Association 
154 V. Rerimassie et al.
for Science and Technology in 2010. In fact, some experts, such as the Chinese 
scientist Yang Huanming, expressed their concern about the influence of criti-
cal public opinion in the developed countries on public perceptions in China and 
called for positive publicity for synthetic biology (Yang 2011). Another Chinese 
scientist, Du Lin, advocated efforts to create a consensus that the discussion of 
ethical and biosafety issues relating to synthetic biology should not hinder syn-
thetic biology research in China. In his view, such a discussion should serve the 
purpose of responding to future international opposition, rather than hindering 
China’s development in this field of research (Du 2011). Progress therefore seems 
to be dominant value in the Chinese risk discourse.
11.4.3  Discourses on Power and Control
On one hand, synthetic biology may provide opportunities to address the grand 
challenges societies are facing, including those relating to health, energy and sus-
tainability. On the other hand, synthetic biology may give rise to risks and ethical 
concerns. In a response to this tension, a recent statement by the Global Network 
of Science Academies called for a global commitment regarding synthetic biology 
(IAP 2014a). According to IAP chairman Volker ter Meulen, it is time to settle 
the ‘synthetic controversy’ (ter Meulen 2014). He notes that if synthetic biology 
is to thrive, the world needs to decide now how the field should be regulated and 
supported. In a comment in The Guardian, science and technology studies scholar 
Jack Stilgoe (2014) responded:
My question is why we, the public, are shut out of the conversation about benefits. 
‘Realising the potential’ of SynBio is talked about as though that potential is pre-ordained. 
It isn’t. SynBio will become what scientists, innovators, users, regulators and others make 
of it. It could be used to create brilliant, emancipatory, subversive, public-value inno-
vation, or it could bolster existing power structures. The direction will depend on who 
is involved, what they value, what research gets done, how intellectual property (IP) is 
arranged and more.
So who gets to decide the direction in which synthetic biology should develop and 
under what conditions? In other words: who gets to exercise the power and control 
over synthetic biology?
Our case studies found a strongly developed discourse on this topic only in the 
EU. The main actors are government and the scientific community, but civil soci-
ety is also making its mark (ETC Group 2007; Roco 2008; Tait 2009; IRGC 2010; 
EASAC 2010; Zhang et al. 2011; FOE et al. 2012; ERASynBio 2014). Largely 
inspired by earlier bad experiences with the public reception of technologies, 
both policymakers and the scientific community feel the need to involve stake-
holders and the broader public early in the development of synthetic biology. The 
aim is that such involvement, besides addressing ethical, legal and social issues 
head on, allows synthetic biology to be better embedded in society, which reso-
nates well with the European striving towards responsible research and innovation 
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(EC 2013). In order to foster responsible research and innovation in the field of 
synthetic  biology, the European Commission for instance funded the Synenergene 
programme (2013–2017), which is dedicated to responsible research and innova-
tion and public engagement in synthetic biology (Synenergene 2014). Furthermore, 
European policymakers and the scientific community call attention to issues that 
require a delicate balance, such as devising forward-looking re gulation without 
stifling innovation and maintaining the equilibrium between scientific freedom 
and self-regulation vis-à-vis state-driven regulation and coercion. This latter form 
of hard government is particularly advocated by internationally operating NGOs 
such as Friends of the Earth and the Action Group on Erosion, Technology and 
Concentration, or ETC Group. As a result, the European governance landscape of 
synthetic biology is already rather complex, even while synthetic biology is still pre-
dominantly confined to the laboratory.
Turning to the Indian case, the Indian task force also recommends that ethi-
cal, legal and social implications should be addressed and public opinion mapped 
upfront, rather than technological development alone being stimulated as a top 
priority. To substantiate this stance, it refers to the negative consequences of pre-
maturely pushing biofuels. In addition, the task force raises the tension between 
open-source initiatives and rigid intellectual property approaches, as these relate to 
the Indian values of access, equity and inclusion.
The Chinese discourse shows a different picture, namely that the development 
and management of synthetic biology are largely in the hands of the government 
and the scientific community, and are considered sufficient so far (Zhang 2014).
11.4.4  Synthetic Biology and Lay Morality
Public reception is crucial for the course of development of a technology. To put it 
bluntly: it can make or break a technology. The concerns of members of the public 
may involve potential physical harms, but to a large extent they will also relate 
to non-physical issues: that is, boundaries related to their values and culture that 
should not be overstepped.
However, given its early stage of development, synthetic biology has not yet 
given rise to significant public debate. In fact, even public awareness is rather low.7 
In the EU there is no real active debate so far, apart from the voices of a small 
number of NGOs, but surveys among the general public and organized public dia-
logues already demonstrate a large degree of pluralism, involving a variety of 
issues and values (RAE 2009; Battachary et al. 2010; Rerimassie and Stemerding 
2014; EC 2010). Such issues include concerns regarding biosafety and biosecurity, 
7
 Only in the EU has public awareness of synthetic biology been gauged via surveys. The 2010 
Biotechnology Eurobarometer (EC 2010) revealed that a large majority of EU citizens (83 %) 
had never heard of synthetic biology.
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freedom of research, monopolization and increasing global inequalities, relating to 
a broad spectrum of values, such as citizens’ rights and market freedoms, justice, 
solidarity, equality and sustainability. These issues and values will prove difficult 
to reconcile. This is sure to become a serious challenge for the governance of syn-
thetic biology, given the aspiration to include a wide array of actors and the issues 
they put forward.
China has not seen an active debate on synthetic biology so far. The public hold 
science in high esteem and trust the government’s management of synthetic biol-
ogy. This attitude reflects the Chinese value system, in which, in the pursuit of 
progress and affluence, pragmatism and developmentalism prevail over potential 
risks as long as the latter have not materialized as actual threats (Zhang 2014). 
This fits in well with the findings on Chinese public perceptions of science and 
technology (See Chap. 3).
Unsurprisingly, there is no public debate on synthetic biology in the Indian case 
either. However, a well-known opponent of genetic modification, Vandana Shiva, 
recently voiced criticism of synthetic biology, as did certain environmental groups 
in India (Domicone 2013). The concerns raised mostly relate to socioeconomic 
considerations and values such as equity and access.
11.4.5  Synthetic Biology and Reflective Ethics
In addition to public expressions of lay morality, morality is reflected upon by 
voices in the field of reflective ethics. Such voices may belong to academia or to 
ethics advisory bodies, including groups and organizations engaged in technology 
assessment and the examination of ethical, legal and social (ELSI) implications. 
Have such voices been heard so far in the emerging debate on synthetic biology? 
If so, are they making an impact on science and technology policy-making and 
development?
In the EU there is strong involvement by reflective ethics voices. In fact, the 
European technology assessment and academic communities engaged with syn-
thetic biology early (Douglas and Stemerding 2014). The EU has contributed sub-
stantially to this effort by funding several programmes on ethical, legal and social 
implications, such as SYNBIOSAFE, Synth-Ethics and SYBHEL (for Synthetic 
Biology for Human Health: Ethical and Legal Issues). On one hand, reflective eth-
ics voices analyse and deepen issues and concerns that have already been raised by 
other actors. On the other hand, reflective ethics also enriches debate by address-
ing issues that so far have not played a big part, but might in future. A good exam-
ple is an in-depth analysis of the notion of ‘playing God’ conducted by the EU 
project SYNTH-ETHICS (Link 2011). This notion is considered potentially con-
troversial in the context of synthetic biology since it revives concerns that have 
been voiced regarding earlier biotechnology as well.
Another important contribution was made by the European Group on Ethics, 
which gave a detailed account of EU regulations and the relevant global provisions 
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with regard to biosafety, biosecurity, intellectual property and potential appli-
cations of synthetic biology, and also the international framework of ethics and 
human rights (EGE 2009). On the basis of this international human rights frame-
work, the European Group on Ethics articulates the main values that should guide 
the ethics of synthetic biology, including human dignity, autonomy and respon-
sibility, freedom, equality, solidarity, justice and sustainability—indeed, largely 
 corresponding with the spectrum of European values described in Chap. 5. 
Broadly speaking it is possible to identify four different roles that reflective ethics 
is playing in the emerging debate on synthetic biology:
•	 Articulating values and issues
•	 Highlighting tensions (often hidden) between values
•	 Enriching debate
•	 Translating the articulated values and issues into science and technology 
policy-making
It is perhaps not surprising that such efforts are being made in Europe, since 
 earlier biotechnologies aroused considerable controversy.
In China some reflective ethics voices from academia are heard, but systematic 
reflection on the moral aspects of synthetic biology is generally lacking. In fact, 
ethical reflection has so far mainly been limited to the general introduction and 
citing of foreign views. A few ethics scholars have raised their voice in an appeal 
for issues of risk and ethics to be addressed in more ‘authentic’ ways by surveying 
the important philosophical and cultural factors in Chinese public policy-making 
concerning synthetic biology (Zhai and Renzong 2010). Given China’s social and 
cultural environment and its prevailing pragmatism and developmentalism, little 
public resistance against synthetic biology is expected (Zhang 2014).
In India, too, no clearly visible tradition of reflective ethics can be found, but 
the Indian task force does recommend that ethical issues be addressed in a an 
‘atmosphere of public acceptance and transparency’, given potential sensitivities 
raised by synthetic biology as a science that interferes with life (Srinivas 2014).
11.5  Conclusion and Discussion: Governance Challenges
This chapter has set out to map the evolving debates on synthetic biology in the 
EU, China and India. It has demonstrated that the European debate on synthetic 
biology has already become quite mature, the debate in China is taking form, and 
the Indian debate is slowly emerging (Table 11.1).
Comparing the nature of the debates in the three regions reveals distinct fea-
tures and positions on the pros and cons of synthetic biology. On one hand, these 
debates are informed by differences in the state of the art of synthetic biology in 
the respective regions. On the other, they are informed by region-specific socio-
economic conditions, cultures and value systems. Based on our analysis we have 
identified a number of region-specific governance challenges that will play an 
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important role in the evolution of the debates on synthetic biology in the three 
regions. These challenges are summarized in Table 11.2.
To better understand these governance challenges we should distinguish 
between risk governance and innovation governance. Discourses of risk in the 
three regions are being framed by scientific knowledge and legal regimes that are 
negotiated and established not only in a national or regional context, but also a 
global context. In other words, risk governance has a strong international dimen-
sion. In all three regions we have seen that, in discussions of synthetic biology, 
attention is drawn to issues of biosafety and biosecurity, articulating the need for 
governments to match global standards of regulation laid down in international 
agreements, such as the Cartagena Protocol on Biosafety and the Biological 
Weapon Convention. This global interconnectedness also creates international 
forums in which parties can search for common ground on how to deal with 
biosafety and biosecurity risks in synthetic biology.
In our understanding of innovation governance in the three regions, a global 
perspective is also obviously important, given the dynamics of international com-
petition, exchange and cooperation. At the same time, innovation governance in 
the three regions relates to socioeconomic and socioethical issues that are more 
specifically framed by regional contexts, values and concerns. In Europe, synthetic 
biology is basically funded as ‘blue sky’ research in support of market-driven 
development. In China and India one finds more deliberate attempts at priority set-
ting in the framework of governmental five-year plans. The Chinese government 
has identified synthetic biology as a technology to be prioritized strategically in 
the nation’s applied biotechnological research, especially in the biomedical and 
health care field. The Indian task force synthetic biology report put the emphasis 
on meeting the developmental needs of the country, and identified biofuels as one 
of the key applications.
In these different regional contexts of synthetic biology innovation, the role 
of the public and reflective ethics also differs, raising governance challenges that 
are specific for each region (as indicated in Table 11.2). In Europe, as we have 
seen, experts have emphasized the need to address ethical and safety concerns 
Table 11.1  Overview of synthetic biology discourses in China, the EU and India (shading of 
cells indicates degree of development)
EU China India 
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Lay morality 
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from the very beginning. Studies of the ethical, legal and social implications have 
received active support, and there have been several public dialogue initiatives 
about synthetic biology. The resulting challenge for the European governance of 
synthetic biology is how to balance the range of interests and values of all relevant 
stakeholders.
In China the government is the principal agent in synthetic biology policy-
making, and there has not been much demand for control from scientists or the 
public. The public generally hold science in high esteem, and systematic ethical 
reflection on synthetic biology is mostly lacking. However, there is clear concern 
among scientists that public opinion might be swayed by critical accounts of syn-
thetic biology in the foreign media. How to maintain public trust in the context of 
international public debate thus arises as a key governance challenge in China.
In India, the task force took a broad view of the promotion and regulation of 
synthetic biology, emphasizing its potential benefits but also the need to address 
safety and ethical issues and to take the public into account. However, conven-
tional patterns of budget allocation and established institutional divisions in India 
are not conducive to the development of a broad interdisciplinary field and to 
effectively directing synthetic biology innovation to the country’s socioeconomic 
needs.
What are the implications of these governance challenges for our aim to 
strengthen ‘global ethics’ in science and technology policy-making in a world of 
increasing interconnectedness? Our case study demonstrates that issues articulated 
in public and ethics discourses about synthetic biology are strongly framed by 
debates emerging in a European and American context. Indeed, to the extent that 
these issues are addressed in the Chinese or Indian regional context, they often 
reflect or replicate European public and ethics discourses rather than more specific 
regional values and concerns.
A truly global dialogue will therefore require a strengthening of public and eth-
ics voices in all three regions, in ways that respond to the specific governance chal-
lenges in each region and more specifically reflect regional values and concerns. 
Such a dialogue will also require a global forum to support mutual learning about 
the possibilities and implications of synthetic biology on the basis of international 
exchange and cooperation. We have identified two forums that may play an impor-
tant role in this regard. First, related to the world of synthetic biology innovation, 
we would like to highlight iGEM, the annual International Genetically Engineered 
Machine competition, which attracts student teams from all over the world. In just 
10 years iGEM has developed into a global hub for thousands of young scientists 
to ‘meet and compete’ (Zhang et al. 2011). This global community not only offers 
a fascinating learning environment, it has also promoted an interest in synthetic 
biology among researchers in China, and could do so in India as well. Moreover, 
and most importantly for a global ethics in synthetic biology, iGEM requires teams 
to include in their projects ‘policy and practices’ work, which stimulates a global 
exchange and dissemination of ideas about biosafety and biosecurity, questions of 
intellectual property, ethics and public engagement in the emerging field of syn-
thetic biology. Second, from the perspective of international public policy making, 
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we see an important role for the United Nations Educational, Scientific and 
Cultural Organization (UNESCO). Over the course of time, UNESCO has been 
manifesting itself more and more as an important global ethics forum. In 2005 the 
general conference of UNESCO pioneered in this regard by acclamation of the 
Universal Declaration on Bioethics and Human Rights. For the first time in history, 
such a large number of UN member States committed themselves and the interna-
tional community to respect and apply fundamental principles of bioethics set forth 
within a single document (UNESCO 2006). Therefore, we consider this an excel-
lent opportunity to build on in dealing with emerging science and technology.
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